Genentech/Curis To Reformulate Basal Cell Carcinoma Topical Treatment
Preliminary Phase I results show histological clearance, but less clinical activity than anticipated with Hedgehog antagonist, Curis says.
Preliminary Phase I results show histological clearance, but less clinical activity than anticipated with Hedgehog antagonist, Curis says.